TY - JOUR
T1 - International validation of the EORTC QLQ‐CLL17 questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia
AU - Oerlemans, Simone
AU - Efficace, Fabio
AU - Kieffer, Jacobien M.
AU - Kyriakou, Charalampia
AU - Xochelli, Aliki
AU - Levedahl, Kerstin
AU - Petranovic, Duska
AU - Borges, Fabio Cardoso
AU - Bredart, Anne
AU - Shamieh, Omar
AU - Gziskevicius, Laimonas
AU - Lehmann, Jens
AU - Scholz, Christian W.
AU - Caocci, Giovanni
AU - Molica, Stefano
AU - Stamatopoulos, Kostas
AU - Panteliadou, Alkistis‐kyra
AU - Papaioannou, Maria
AU - Alrjoob, Waleed
AU - Baliakas, Panagiotis
AU - Rosenquist, Richard
AU - Malak, Sandra
AU - Miranda, Ana
AU - Cocks, Kim
AU - van de Poll‐Franse, Lonneke
N1 - The project was allocated an EORTC Quality of Life Group (QLG) grant for module development, Phase IV
PY - 2022
Y1 - 2022
N2 - Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.
AB - Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.
KW - CHLORAMBUCIL
KW - CRITERIA
KW - EORTC
KW - FEAR
KW - LYMPHOMA
KW - PRO
KW - QLQ-C30
KW - REPORTED OUTCOMES
KW - RITUXIMAB
KW - THERAPY
KW - TRIALS
KW - chronic lymphocytic leukaemia
KW - psychometric properties
KW - quality of life
KW - questionnaire
KW - symptoms
UR - http://www.scopus.com/inward/record.url?scp=85130005666&partnerID=8YFLogxK
U2 - 10.1111/bjh.18072
DO - 10.1111/bjh.18072
M3 - Article
SN - 0007-1048
VL - 197
SP - 431
EP - 441
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 4
ER -